Thus, we hypothesized that frequency of ALDH-positive cells would predict for response to tamoxifen treatment, and we analyzed ALDH1 in 322 ER+ BC samples taken prior to a randomized trial of tamoxifen versus no systemic treatment. This evidence concerns the gene ESR1 and breast cancer.